A study of glioma tissue to learn what makes these tumors different
Official title: Metabolomics and Transcriptomics of Low- and High-Grade Gliomas
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study looks closely at brain tumor tissue to find new tumor groups.
Read our full plain-language summary
What the trial team says
The goal of this observational study is to better define the molecular profile of rare brain tumors (gliomas) based on the levels of their metabolites and transcripts (the intermediate step between DNA information and proteins). The main question it aims to answer is to identify new brain tumour subgroups of clinical relevance that might explain the very different history these patients might follow. Additionally, studies on gliomas require cellular cultures and animal models for the development of new medications, but these models are still scarce and rudimental for many types of gliomas. The second aim of this study is to implement better models for these tumors, for a more effective development of new medications. Patients enrolled in this study will not undergo any additional procedures with respect to those necessary for gold-standard management of these brain tumors. A small sample of the resected tumour will be used for advanced analyses investigating the metabolic and transcriptomic profile and used for temptative establishment of cellular cultures and animal models of these pathologies.
Key facts
- Registry number
- NCT07832734
- Conditions studied
- IDH Wildtype Glioblastoma, IDH Mutant Lower-Grade Gliomas
Where it is running
This trial lists 1 site.
-
Lombardy
- IRCCS Galeazzi-Sant'Ambrogio (Milan)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.